相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Plasma β amyloid and the risk of Alzheimer disease and dementia in elderly men
Johan Sundelof et al.
ARCHIVES OF NEUROLOGY (2008)
Amyloid plaque imaging in vivo: current achievement and future prospects
Agneta Nordberg
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Epitope mapping and neuroprotective properties of a human single chain FV antibody that binds an internal epitope of amyloid-beta 1-42
R. S. Solorzano-Vargas et al.
MOLECULAR IMMUNOLOGY (2008)
PET imaging of amyloid deposition in patients with mild cognitive impairment
Anton Forsberg et al.
NEUROBIOLOGY OF AGING (2008)
Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils
Gernot Habicht et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
β-amyloid imaging and memory in non-demented individuals:: evidence for preclinical Alzheimer's disease
Kerryn E. Pike et al.
BRAIN (2007)
In vitro characterization of Pittsburgh compound-B binding to Lewy bodies
Michelle T. Fodero-Tavoletti et al.
JOURNAL OF NEUROSCIENCE (2007)
CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment
F. H. f Bouwman et al.
NEUROBIOLOGY OF AGING (2007)
In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques
Joseph F. Poduslo et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Imaging β-amyloid burden in aging and dementia
C. C. Rowe et al.
NEUROLOGY (2007)
PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment
N. M. Kemppainen et al.
NEUROLOGY (2007)
Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease
Neill R. Graff-Radford et al.
ARCHIVES OF NEUROLOGY (2007)
Learning decreases Aβ*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice
Lauren M. Billings et al.
JOURNAL OF NEUROSCIENCE (2007)
Prediction of Alzheimer's disease using the CSF A beta 42/A beta 40 ratio in patients with mild cognitive impairment
Oskar Hansson et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2007)
CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies
M. Bibl et al.
JOURNAL OF NEURAL TRANSMISSION (2006)
Blood-borne factors inhibit Alzheimer's β-amyloid fibril formation in vitro
Kenjiro Ono et al.
EXPERIMENTAL NEUROLOGY (2006)
Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: New cues into the human disease?
Eva Carro et al.
NEUROBIOLOGY OF AGING (2006)
Cerebrospinal fluid tau and β-amyloid in Alzheimer patients, disease controls and an age-matched random sample
Bernd Ibach et al.
NEUROBIOLOGY OF AGING (2006)
Advanced glycation end products - Sparking the development of diabetic vascular injury
Alison Goldin et al.
CIRCULATION (2006)
Plasma Aβ1-40 and Aβ1-42 and the risk of dementia:: a prospective case-cohort study
Marieke van Oijen et al.
LANCET NEUROLOGY (2006)
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Randall J. Bateman et al.
NATURE MEDICINE (2006)
Soluble Receptor for Advanced Glycation End Products: From Disease Marker to Potential Therapeutic Target
Diego Geroldi et al.
CURRENT MEDICINAL CHEMISTRY (2006)
High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans
Diego Geroldi et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2006)
Insulin resistance, inflammation, and cognition in Alzheimer's Disease:: Lessons for multiple sclerosis
G. Stennis Watson et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2006)
Differential modulation of plasma β-amyloid by insulin in patients with Alzheimer disease
J. J. Kulstad et al.
NEUROLOGY (2006)
CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
M Bibl et al.
BRAIN (2006)
High density lipoproteins bind Aβ and apolipoprotein C-II amyloid fibrils
LM Wilson et al.
JOURNAL OF LIPID RESEARCH (2006)
The role of gonadotropins in Alzheimer's disease
Anna M. Barron et al.
ENDOCRINE (2006)
A specific amyloid-β protein assembly in the brain impairs memory
S Lesné et al.
NATURE (2006)
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
O Hansson et al.
LANCET NEUROLOGY (2006)
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans
AM Fagan et al.
ANNALS OF NEUROLOGY (2006)
Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis
E. Carro et al.
NEUROBIOLOGY OF AGING (2006)
Insulin resistance syndrome and Alzheimer's disease: Age- and obesity-related effects on memory, amyloid, and inflammation
S Craft
NEUROBIOLOGY OF AGING (2005)
Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease
S Rovio et al.
LANCET NEUROLOGY (2005)
Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers
K Iqbal et al.
ANNALS OF NEUROLOGY (2005)
Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia
E Emanuele et al.
ARCHIVES OF NEUROLOGY (2005)
Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension
D Geroldi et al.
JOURNAL OF HYPERTENSION (2005)
Plasma amyloid β protein 42 in non-demented persons aged 75 years:: Effects of concomitant medication and medial temporal lobe atrophy
I Blasko et al.
NEUROBIOLOGY OF AGING (2005)
Familial Alzheimer disease:: Decreases in CSF Aβ42 levels precede cognitive decline
M Moonis et al.
NEUROLOGY (2005)
Cerebrospinal fluid tau, Aβ1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia
JP Jia et al.
NEUROSCIENCE LETTERS (2005)
Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men
C Falcone et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease
PA Adlard et al.
JOURNAL OF NEUROSCIENCE (2005)
CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment
SK Herukka et al.
NEUROLOGY (2005)
Physical activity, APOE genotype, and dementia risk: Findings from the Cardiovascular Health Cognition Study
LJ Podewils et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2005)
Environmental enrichment reduces Aβ levels and amyloid deposition in transgenic mice
O Lazarov et al.
CELL (2005)
Increased Cerebrospinal Fluid A beta 38/A beta 42 Ratio in Alzheimer Disease
Pankaj D. Mehta et al.
NEURODEGENERATIVE DISEASES (2005)
Natural oligomers of the amyloid-protein specifically disrupt cognitive function
JP Cleary et al.
NATURE NEUROSCIENCE (2005)
Engineered antibody fragments and the rise of single domains
P Holliger et al.
NATURE BIOTECHNOLOGY (2005)
Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Z Arvanitakis et al.
ARCHIVES OF NEUROLOGY (2004)
Dimeric amyloid β protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease
T Kawarabayashi et al.
JOURNAL OF NEUROSCIENCE (2004)
Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer's disease patients
R Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau
P Lewczuk et al.
NEUROBIOLOGY OF AGING (2004)
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B
WE Klunk et al.
ANNALS OF NEUROLOGY (2004)
Reduced levels of Aβ 40 and Aβ 42 in brains of smoking controls and Alzheimer's patients
E Hellström-Lindahl et al.
NEUROBIOLOGY OF DISEASE (2004)
ApoE and clusterin cooperatively suppress Aβ levels and deposition:: Evidence that ApoE regulates extracellular Aβ metabolism in vivo
RB DeMattos et al.
NEURON (2004)
LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms
R Deane et al.
NEURON (2004)
Atorvastatin-induced activation of Alzheimer's α secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding
S Parvathy et al.
JOURNAL OF NEUROCHEMISTRY (2004)
Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: Implications for Alzheimer's disease intervention
LX Zhao et al.
JOURNAL OF NEUROSCIENCE (2004)
Alzheimer's disease Aβ vaccine reduces central nervous system Aβ levels in a non-human primate, the Caribbean Vervet
CA Lemere et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
A modified β-amyloid hypothesis:: intraneuronal accumulation of the β-amyloid peptide -: the first step of a fatal cascade
O Wirths et al.
JOURNAL OF NEUROCHEMISTRY (2004)
RAGE (Yin) versus LRP (Yang) balance regulates Alzheimer amyloid β-peptide clearance through transport across the blood-brain barrier
R Deane et al.
STROKE (2004)
Systemic catabolism of Alzheimer's Aβ40 and Aβ42
J Ghiso et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
APP intracellular domain is increased and soluble Aβ is reduced with diet-induced hypercholesterolemia in a transgenic mouse model of Alzheimer disease
AJ George et al.
NEUROBIOLOGY OF DISEASE (2004)
The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught?
G Verdile et al.
PHARMACOLOGICAL RESEARCH (2004)
Genetic variants in a haplotype block spanning IDE are significantly associated with plasma A beta 42 levels and risk for Alzheimer disease
N Ertekin-Taner et al.
HUMAN MUTATION (2004)
Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death
MA Leissring et al.
NEURON (2003)
Plasma Aβ40 and Aβ42 and Alzheimer's disease -: Relation to age, mortality, and risk
R Mayeux et al.
NEUROLOGY (2003)
CSF markers for Alzheimer's disease:: Total Tau, phospho-tau and Aβ42
N Andreasen et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2003)
Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype
S Craft et al.
PSYCHONEUROENDOCRINOLOGY (2003)
Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
JM Orgogozo et al.
NEUROLOGY (2003)
Age but not diagnosis is the main predictor of plasma amyloid β-protein levels
H Fukumoto et al.
ARCHIVES OF NEUROLOGY (2003)
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
R Deane et al.
NATURE MEDICINE (2003)
Insulin increases CSF Aβ42 levels in normal older adults
GS Watson et al.
NEUROLOGY (2003)
Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease
GL Vega et al.
ARCHIVES OF NEUROLOGY (2003)
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide:: a case report
JAR Nicoll et al.
NATURE MEDICINE (2003)
Brain repair and neuroprotection by serum insulin-like growth factor I
E Carro et al.
MOLECULAR NEUROBIOLOGY (2003)
Aging-related down-regulation of neprilysin, a putative β-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of β-amyloid plaques
J Apelt et al.
NEUROSCIENCE LETTERS (2003)
Expanding the association between the APOE gene and the risk of Alzheimer's disease:: possible roles for APOE promoter polymorphisms and alterations in APOE transcription
SM Laws et al.
JOURNAL OF NEUROCHEMISTRY (2003)
CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
D Strozyk et al.
NEUROLOGY (2003)
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting A beta amyloid deposition and toxicity in Alzheimer disease - A pilot phase 2 clinical trial
CW Ritchie et al.
ARCHIVES OF NEUROLOGY (2003)
Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon 4 allele
DG Cook et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Plasma and cerebrospinal fluid alpha-1-antichymotrypsin levels in Alzheimer's disease: Correlation with cognitive impairment
ST DeKosky et al.
ANNALS OF NEUROLOGY (2003)
Aβ immunization and anti-Aβ antibodies:: potential therapies for the prevention and treatment of Alzheimer's disease
DM Holtzman et al.
ADVANCED DRUG DELIVERY REVIEWS (2002)
Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings
D Stern et al.
ADVANCED DRUG DELIVERY REVIEWS (2002)
Serum insulin-like growth factor I regulates brain amyloid-levels
E Carro et al.
NATURE MEDICINE (2002)
Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease
RB DeMattos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Circulating amyloid-β peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions
JB Mackic et al.
VASCULAR PHARMACOLOGY (2002)
Alzheimer disease as a vascular disorder - Nosological evidence
JC de la Torre
STROKE (2002)
Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus
HW Wang et al.
BRAIN RESEARCH (2002)
alpha(2)-macroglobulin deletion polymorphism and plasma levels in late onset Alzheimer's disease
R Scacchi et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2002)
APOE-epsilon 4 and APOE-491A polymorphisms in individuals with subjective memory loss
SM Laws et al.
MOLECULAR PSYCHIATRY (2002)
Variation at the APOE-491 promoter locus is associated with altered brain levels of apolipoprotein E
SM Laws et al.
MOLECULAR PSYCHIATRY (2002)
A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease
LM Refolo et al.
NEUROBIOLOGY OF DISEASE (2001)
Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: Identification of a cellular activation mechanism
LF Lue et al.
EXPERIMENTAL NEUROLOGY (2001)
Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo
K Fassbender et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Plasma α1-antichymotrypsin in Alzheimer's disease;: relationships with APOE genotypes
R Scacchi et al.
NEUROBIOLOGY OF AGING (2001)
Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
N Andreasen et al.
ARCHIVES OF NEUROLOGY (2001)
Neurodegeneration is associated to changes in serum insulin-like growth factors
S Busiguina et al.
NEUROBIOLOGY OF DISEASE (2000)
Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma
H Vanderstichele et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2000)
Clearance of Alzheimer's amyloid-β1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier
M Shibata et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
The α2-macroglobulin gene in AD -: A population-based study and meta-analysis
MN Koster et al.
NEUROLOGY (2000)
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard et al.
NATURE MEDICINE (2000)
Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo
JG Sheng et al.
EXPERIMENTAL NEUROLOGY (2000)
Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease
DM Holtzman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Amyloid-β peptides interact with plasma proteins and erythrocytes:: Implications for their quantitation in plasma
YM Kuo et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Degradation of soluble amyloid β-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains
A Pérez et al.
NEUROCHEMICAL RESEARCH (2000)
α2 macroglobulin and the risk of Alzheimer's disease
RC Dodel et al.
NEUROLOGY (2000)
Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease:: A population-based study of African Americans
RM Evans et al.
NEUROLOGY (2000)
Insulin-like growth factor I - Implications in aging
E Arvat et al.
DRUGS & AGING (2000)
Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease
PD Mehta et al.
ARCHIVES OF NEUROLOGY (2000)
分享论文
